Novel Drug/Biologics Delivery Systems FDA Workshop Slated For July 8
This article was originally published in The Gray Sheet
Executive Summary
FDA is soliciting feedback on regulatory challenges posed by novel drug and biologics delivery systems - and steps the agency can take to ease their regulatory pathway
You may also be interested in...
CDRH Problematic Regulatory Paths Review On Near-Term Agenda – Feigal
The Center for Devices & Radiological Health already is moving to implement agency-wide initiatives that seek to provide guidance for manufacturers of novel products, according to FDA officials
MoCRA Stakeholders Reminded Registration Enforcement Begins 1 July: ‘Do Not Delay!’
The Independent Beauty Association urged stakeholders at its Cosmetic Convergence Symposium to take action to ensure they are meeting requirements of the Modernization of Cosmetics Regulation Act come 1 July, when FDA’s enforcement of the facility and product registration deadline begins. Presenters offered tips from companies that have already completed the process.
Boehringer Ingelheim Overtakes Bayer As Germany’s Biggest Pharma Company
The privately owned company is searching for a successor to Jardiance, while the outcome of US Inflation Reduction Act talks on price cuts to the blockbuster will be revealed in September.